Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Non Operating Income: 2011-2025

Historic Non Operating Income for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to -$3.5 million.

  • Adma Biologics' Non Operating Income fell 21.05% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.2 million, marking a year-over-year increase of 72.94%. This contributed to the annual value of -$13.3 million for FY2024, which is 73.39% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Non Operating Income is -$3.5 million, which was down 29.47% from -$2.7 million recorded in Q2 2025.
  • Adma Biologics' 5-year Non Operating Income high stood at -$1.4 million for Q1 2025, and its period low was -$31.9 million during Q4 2023.
  • In the last 3 years, Adma Biologics' Non Operating Income had a median value of -$3.5 million in 2025 and averaged -$6.4 million.
  • As far as peak fluctuations go, Adma Biologics' Non Operating Income crashed by 416.39% in 2023, and later surged by 88.68% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' Non Operating Income stood at -$3.5 million in 2021, then crashed by 78.50% to -$6.2 million in 2022, then tumbled by 416.39% to -$31.9 million in 2023, then spiked by 88.68% to -$3.6 million in 2024, then declined by 21.05% to -$3.5 million in 2025.
  • Its Non Operating Income was -$3.5 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$1.4 million in Q1 2025.